UK +44 (0)1865 849841
Malaysia +603 2779 0098

NASH Resources

Presentation Videos

Promiscuous drug mechanisms in obesity, diabetes, and NASH; using proteomics to compare benefits across multiple organ systems

Stephen William, Chief Medical Officer, SomaLogic, USA

What factors contribute to successful weight loss?

Dimitrios Koutoukidis is Senior Research Fellow at The University of Oxford, UK

Non-invasive diagnosis and assessment of NASH in real world clinical practice

Sid Barritt is Director in the UNC Liver Center at The University of North Carolina, USA

Fully automated NASH quantification using Deep Learning Applications

Rutger Fick is Senior AI Lead at Tribun Health

Machine Learning in NAFLD

Hamish Miller Clinical Research Fellow and PhD Student, Oxford University & Queen Mary University of London

Plasma TREM2 as a potential novel non-invasive NASH biomarker

Jonas Heilskov Graversen, Associate Professor, University of Southern Denmark, Denmark

Recent insights in the pathophysiology and treatment of pediatric NAFLD

Sander Lefere is Postdoctoral Researcher at Ghent University, Belgium

Nonalcoholic steatohepatitis (NASH) is a serious, progressive disease

Diana Chung is Chief Development Officer at Terns Pharmaceuticals, USA

Advancement in Therapeutics: Anti-Obesity Medications

Scott Harris, Chief Medical Officer, Altimmune, USA

Exercise as medicine for patients with NAFLD

Jonathan Stine Fatty Liver Program Director, Liver Center Research Director, Penn State Health – Milton S. Hershey Medical Center, USA

The relationship between type 2 diabetes and NAFLD and relevant treatments for NAFLD

Chris Byrne Professor of Endocrinology & Metabolism, University of Southampton, UK

Advancement of rencofilstat in NASH phase 2 – evaluating both structural and functional data

Todd Hobbs, Chief Medical Officer, Hepion Pharmaceuticals, USA

Lanifibranor, a balanced pan-PPAR agonist, improves markers of cardiometabolic health in patients with NASH

Michael Cooreman is Chief Medical Officer at Inventiva, USA, France

Administration of glutaredoxin in hepatocytes is a potential therapeutic against NASH progression

Reiko Matsui is Assistant Professor at Boston University, USA

Humans as the model: human fatty liver perfusion to bypass poorly predictive animal models

Quin Wills is CSO at Ochre-Bio, UK

Vascular alterations in NASH and NASH cirrhosis

Sven Francque, Chairman in the Division of Gastroenterology and Hepatology, Antwerp University Hospital, Belgium

The Emerging Weight Loss Therapeutics and Implications for the NASH Treatment Paradigm

Scott Harris, Chief Medical Officer at Altimmune, USA

Innovating in NASH cirrhosis

Pol Boudes, Chief Medical Officer, Galectin Therapeutics,USA

Getting GRIP on NASH: Implementation of an International Clinical Screening Program

Rick Grobbee, Chief Scientific Officer, Julius Clinical and Professor of Clinical Epidemiology, University Medical Center (UMC) Utrecht, The Netherlands

Systematic evaluation of non-invasive imaging and serum-based tests for detecting NAFLD

Ferenc Emil Mozes, Postdoctoral Research Assistant, OCMR at the University of Oxford, UK

Integrating Metabolomics into NASH R and D

Kari Wong, Associate Director, Scientific Strategy, Metabolon, USA

CRV431 Clinical Plans in NASH

Todd Hobbs, Chief Medical Officer, Hepion Pharmaceuticals Inc

Validation and comparison of the diagnostic, performance of HepaFat-Scan® for assessment of liver steatosis by MRI

Tim St Pierre, Chief Scientific Researcher, Resonance Health

Bariatric surgery in NASH: benefits and pitfalls

Anja Geerts, Professor, Department of Gastroenterology and Hepatology, University of Gent

Treating NASH through a unique mode of action with tesamorelin

Christian Marsolais, Senior Vice President and Chief Medical Officer, Theratechnologies, Canada

Histological scoring systems from the pathologist point of viewource Title

Valerie Paradis, Professor in Pathology, Chair, Pathology Dept, Beaujon Hospital, Clichy, INSERM

Safety and Efficacy of CRV431 in NASH: A Quantitative Systems Pharmacology Analysis

Patrick Mayo, SVP Clinical Pharmacology and Analytics, Hepion Pharmaceuticals Inc.

Drug Development for NASH with Fibrosis: A Regulatory Perspective

George Makar, Medical Officer, Food and Drug Administration, FDA

Challenges of assessing efficacy of drugs in NASH treatment

Sven Francque, Chairman, Division of Gastroenterology and Hepatology, Antwerp University Hospital, Belgium

Prebiotic xylo-oligosaccharides (XOS) ameliorate non-alcoholic fatty liver disease (NAFLD)esource Title

Satu Pekkala, Academy of Finland Research Fellow, Adjunct professor, University of Jyväskylä

Inhibiting NOX enzymes to treat mulitple diseases with high medical need

Alexandre Grassin

The EMA reflection paper on chronic liver disease and its implications for drug development in NASH

Elmer Schabel

Genetics of progressive NAFLD

Luca Valenti


NASH: Accelerating awareness, identification and clinical trial enrolment

Sven Francque, Antwerp University Hospital; Norbert Stefan, Helmholtz Centre Munich and the University of Tubingen; Joseph Toerner, FDA; Pierre Bedossa University of Paris, and the team from AES


Wrapping Up Day Two Of The Fourth Global NASH Congress — Drugs, Lifestyles and Health Policy


Day Two At The 4th Global NASH Congress — Many New Drugs and Non-Pharmacologic Interventions


Day One At The 4th Global NASH Congress — Diagnostics, Drugs And Regulatory Issues


Pharmacotherapy Themes At The 4th Global NASH Congress


Patient-Centric Themes At The 4th Global NASH Congress


Non-Invasive Testing Themes At The 4th global NASH Congress


Previewing the 4th Global NASH congress


Poster Presentations

Development of a diet-induced disease-mimicking in vitro model of non-alcoholic steatohepatitis / fibrosis

Haysam Ahmed, Hossein Eslami Amirabadi, Karin Toet, Elsbet Pieterman, Robert Ostendorf, Roeland Hanemaaijer, Evita van de Steeg, Bob de Water, Ivana Bobeldijk and Geurt Stokman

Presentation Slides

A biomarker of fibrosis resolution, CTX-III, increases after bariatric surgery in early NAFLD patients with histological liver improvements

Ida Lønsmann, Industrial Research Fellow, Nordic Bioscience

Thioacrylamide-derivatives with hepato-protective and anti-fibrotic activity

Juergen Eckel, CureDiab Metabolic Research GmbH Düsseldorf, Germany

Targeting different pathways of NASH pathogenesis using single and combination therapies

Eric Hughes, Global Development Unit Head, Immunology & Dermatology, Novartis

Modulation of the mitochondrial pyruvate carrier (MPC) as a treatment for NASH

Jerry R. Colca, Vice President for R&D, Cirius Therapeutics

Body composition in NASH clinical trials

Jonathan Riek, Vice President of Musculoskeletal & Metabolic Imaging, BioTelemetry Research

Liver biopsy as the gold standard for diagnosis

Pierre Bedossa, President of the European Society of Pathology

FDA Regulatory considerations for NASH clinical trial endpoints

Stephanie O. Omokaro, Lead Medical Officer, DGIEP Liver Team IV, Center for Drug Evaluation and Research, Food and Drug Administration

Imaging based technologies for NAFLD in clinical practice

Victor de Ledlinghen, Professor, Investigation Center of Liver Fibrosis, Bordeaux University Hospital

GKT831: A novel PII anti-fibrotic small molecule

Alexandre Grassin, VP Finance and Administration, Genkyotex. Switzerland

The EMA reflection paper on chronic liver disease and its implications for drug development in NASH

Elmer Schabel, Clinical Assessor, Licensing Division 2, Federal Institute for Drugs and Medical Devices (BfArM), Germany

Genetics of progressive nonalcoholic fatty liver disease

Luca Valenti, Associate Professor of Internal Medicine, University of Milan, Italy

Application of non-invasive tests for liver fibrosis

William Rosenberg, Peter Scheuer Chair in Liver Diseases, Deputy Director, UCL Institute for Liver and Digestive Health

Discovery and validation of protein signatures for NAFLD risk and NASH status

Stephen Williams, Chief Medical officer, SomaLogic

The Poxel NASH portfolio: PXL770 and PXL065 two Differentiated Drug Candidates with Complementary Mechanisms of Action for the Treatment of NASH

Sebastien Bolze, Executive Vice President, Non Clinical Development, Co-Founder, Poxel

Dual GLP-1 Agonists in the Treatment Metabolic & Liver Dysfunction in NASH

Scott Harris, Chief Medical Officer, Altimmune

Multiparametric MRI for the evaluation of NAFLD

Michael Pavlides, Head of Liver Imaging, Oxford Centre for Clinical Magnetic Resonance Research (OCMR)

Sustained FXR agonist as optimized, best-in-class treatment for NASH

Hubert Chen, Chief Medical Officer, Metacrine

Identifying patients with risk of adverse outcomes – where should we look more closely?

Hannes Hagström, Consultant in Hepatology, Unit of Hepatology, Karolinska University Hospital, Sweden

The role of lysosomal acid lipase activity in NAFLD/NASH pathogenesis

Stefano Ginanni Corradini, Associate Professor,Division of Gastroenterology, Department of Translational and Precision Medicine, University “Sapienza” of Rome Italy

NASH Trial Recruitment: The AES Solution

Elias Ketiar, Medical Director, Accelerated Enrollment Solutions

RNAi strategy for the treatment of NASH: focus on astrocyte elevated Gene-1 (AEG-1)

Devanand Sarkar, Professor, Virginia Commonwealth University, USA

Metabolic changes and biomarkers preceding and associated with NASH

Daniel Sikkema, Vice President, Accelerator and Pharma services for Quanterix Corporation

How the gut talks to the brain to impact the liver

Carel le Roux, Professor of Experimental Pathology, Conway Institute, Diabetes Complications Research Centre, University College Dublin, Ireland

Diabetes and NAFLD: a vicious spiral affecting both diseases

Chris Byrne, Professor Endocrinology & Metabolism, Human Development and Health Academic Unit, Faculty of Medicine, The \Institute of Developmental Sciences (IDS), University of Southampton, UK

The impact of medical devices on diabetes and fatty liver disease

Alex Miras, Senior Clinical Lecturer in Endocrinology, Department of Metabolism, Digestion and Reproduction, Imperial College, UK

Resmetirom, a highly beta selective liver-directed thyroid hormone receptor beta agonist for the treatment of NASH

Rebecca Taub, Chief Medical Officer and President, Research & Development, Madrigal Pharmaceuticals, USA

Endpoint Adjudication Best Practices for NASH trials

Bindi K. Shah, Chief Medical Officer, WCG – ACI Clinical